Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b

Abstract The transcription factor STAT5b is a target for tumour therapy. We recently reported catechol bisphosphate and derivatives such as Stafib-1 as the first selective inhibitors of the STAT5b SH2 domain. Here, we demonstrate STAT5b binding of catechol bisphosphate by solid-state nuclear magneti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nagarajan Elumalai, Angela Berg, Stefan Rubner, Linda Blechschmidt, Chen Song, Kalaiselvi Natarajan, Jörg Matysik, Thorsten Berg
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/7eb0fb05f08d4517a3fb77233ccd9bc2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!